15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Vanderbilt University, La Jolla Pharmaceutical deal

La Jolla and the university partnered to develop small molecule kinase inhibitors discovered at the university, which selectively block members of the bone morphogenetic protein receptor type I (BMPRI) family. La Jolla will fund the...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

LJPC-6417 regulatory update

La Jolla said FDA granted Orphan Drug designation for its LJPC-6417 to treat fibrodysplasia ossificans progressiva, a rare inherited disorder where muscle and connective tissue are replaced by bone. The kinase inhibitor targeting bone morphogenetic...